56541

B.M.

My patient, based on last name, is Chara Gutierrez. Chara Gutierrez is a 58-year-old female who presents to the clinic with a one-month history of fatigue, joint pain, swelling, and stiffness involving her hands, fingers, toes, and feet. Her pain is worse after periods of immobility. Imaging and further evaluation confirmed a diagnosis of rheumatoid arthritis. She is returning for follow-up so treatment can be started to control her symptoms and slow progression of the disease.

Her medical history includes hypertension and type 2 diabetes. Her current medications are captopril 25 mg by mouth every 12 hours and metformin 500 mg by mouth twice daily. She has no known allergies. She is a former smoker, drinks alcohol on weekends, and has a BMI of 36.6

2. Chara is newly diagnosed and, assuming she has not previously received a DMARD for another condition, would be considered DMARD-naÃ¯ve. For a DMARD-naÃ¯ve patient with moderate-to-high disease activity, the CPG guideline recommends methotrexate monotherapy over hydroxychloroquine, sulfasalazine, biologic DMARDs, or targeted synthetic DMARDs. I would initiate oral methotrexate, which is preferred over subcutaneous methotrexate when beginning therapy.

The guideline recommends titrating methotrexate to at least 15 mg once weekly within 4â€“6 weeks. I would also prescribe folic acid supplementation to reduce methotrexate-related adverse effects and decrease the likelihood of B12-related anemia or other related conditions. Methotrexate is necessary because it treats the underlying inflammatory disease and can slow disease progression and prevent permanent joint damage.

For additional control of Charaâ€™s pain and inflammation while methotrexate begins working, I would consider naproxen 250â€“500 mg orally twice daily with food as needed. This would be for symptom control only and would not replace DMARD therapy. Because Chara has hypertension and takes captopril, I would want to confirm adequate renal function and monitor her blood pressure. NSAIDs can decrease the antihypertensive effect of ACE inhibitors and increase the risk for renal impairment.

I would try to avoid routine systemic glucocorticoids. If they are necessary as short-term bridge therapy while waiting for methotrexate to become effective, I would use the lowest effective dose for the shortest duration possible. This is particularly important for Chara because she has type 2 diabetes and obesity, and systemic glucocorticoids could worsen her glucose control and increase other metabolic and bone-related risks due to her age and sex.

Finally, I would not start methotrexate until completing additional baseline assessment. Her weekend alcohol use needs to be quantified because methotrexate can cause hepatotoxicity, and significant alcohol consumption or underlying liver disease could alter the treatment plan. Her BMI of 36.6 and type 2 diabetes also increase concern for underlying metabolic fatty liver disease. If her baseline evaluation is reassuring, I would proceed with oral methotrexate. If oral methotrexate is not tolerated or she does not reach her treatment goal, I would first optimize methotrexate therapy, including considering subcutaneous administration, before moving away from methotrexate.

3. Before initiating treatment, I would want a more complete assessment of Charaâ€™s liver and kidney function. Her history states that she drinks alcohol on weekends, but I would need to determine how much and how frequently she drinks. Methotrexate can cause hepatotoxicity, and alcohol can further increase this risk. I would obtain baseline AST, ALT, alkaline phosphatase, bilirubin, and albumin. Charaâ€™s BMI of 36.6 and type 2 diabetes also increase her risk for metabolic-associated fatty liver disease. If her history or laboratory findings raise concern, I would consider additional assessment for liver fibrosis and possible hepatology consultation before initiating methotrexate. I would also screen for hepatitis B and C before immunosuppressive treatment.

I would obtain a complete renal assessment including BUN, serum creatinine, eGFR, and electrolytes, particularly potassium. Methotrexate is primarily eliminated by the kidneys, so decreased renal function can increase methotrexate concentrations and toxicity. Renal function is also important because Chara takes captopril and I am considering naproxen for symptom control. ACE inhibitors such as captopril dilate the efferent arteriole, while NSAIDs decrease renal prostaglandin production and constrict the afferent arteriole. Together, they can decrease glomerular filtration pressure and increase the risk for acute kidney injury. NSAIDs can also cause sodium and water retention, increase blood pressure, and decrease the antihypertensive effect of captopril. Because ACE inhibitors can increase potassium, I would also monitor for hyperkalemia.

I would obtain a baseline CBC with differential and platelet count because methotrexate can cause bone marrow suppression. These results would provide baseline values for comparison after treatment begins. I would also obtain a current A1C and glucose to assess Charaâ€™s diabetes control. This would be especially important if short-term glucocorticoid therapy becomes necessary because glucocorticoids can cause significant hyperglycemia.

Before recommending regular naproxen, I would ask Chara about any history of peptic ulcer disease, GI bleeding, kidney disease, cardiovascular disease, or previous problems with NSAIDs. I would also complete a full medication reconciliation that includes OTC medications, vitamins, and herbal supplements. I would specifically ask about her use of ibuprofen, naproxen, aspirin, or other OTC pain medications because these could increase renal, GI, or medication-related risks.

I would also assess Charaâ€™s infection history and vaccination status before beginning immunosuppressive therapy. Hepatitis screening is important before methotrexate, and TB screening would become particularly important if treatment eventually requires a biologic or targeted synthetic DMARD. Vaccinations should be reviewed and updated when appropriate before greater immunosuppression is required.

Patient education would be an important part of the treatment plan. I would make sure Chara understands that methotrexate for RA is taken once weekly, not daily, because daily dosing errors can cause severe toxicity. I would discuss the purpose of folic acid, potential adverse effects, alcohol use, signs of infection or toxicity that should be reported, and the importance of keeping laboratory appointments.

I would also discuss Charaâ€™s insurance coverage, medication costs, and ability to consistently obtain and take her medications. Although oral methotrexate is generally inexpensive, laboratory monitoring, specialist visits, and future therapies could affect adherence. If her disease eventually requires a biologic or targeted synthetic DMARD, cost and insurance authorization could become even more significant. I would assess whether she can manage a once-weekly medication schedule, attend regular laboratory and follow-up appointments, and safely manage her medications at home. Any financial or adherence barriers should be identified early.

I would also discuss physical activity and weight management with Chara. Her current joint pain and stiffness may make exercise difficult, so I would consider referral to physical therapy or an appropriate exercise program to develop a safe, individualized plan. Regular low-impact aerobic activity and strengthening exercises can help maintain joint mobility, muscle strength, and physical function. Increased physical activity may also help with weight management and improve her diabetes, hypertension, and overall cardiovascular risk. I would discuss realistic activity goals with Chara rather than allowing her current joint symptoms to lead to increasing inactivity.

After treatment begins, I would follow Charaâ€™s CBC, liver enzymes, and renal function closely and continue periodic monitoring throughout therapy. I would also reassess her joint pain, swelling, stiffness, functional status, and overall RA disease activity. Treatment should follow a treat-to-target approach. If she does not reach the desired treatment goal, therapy should be optimized or adjusted rather than continuing an ineffective regimen.

Are you struggling to create a sound and comprehensive nursing paper? Do you feel overwhelmed with the amount of time and effort it takes to write a good piece? Are you looking for the best nursing paper writing service that can assist you in your nursing paper needs? Look no further than our skilled team of professional writers who specialize in providing high-quality papers with the best nursing paper writing services reviews. Make your order at nursingpaperhelp.com